Drug Information

Drug General Information
Drug ID
D0J6NG
Former ID
DIB007600
Drug Name
OPA-6566
Indication Glaucoma [ICD9: 365; ICD10:H40-H42] Phase 1/2 [523581]
Company
Acucela; otsuka pharmaceutical
Target and Pathway
Target(s) Adenosine A2a receptor Target Info Agonist [550203]
KEGG Pathway Rap1 signaling pathway
Calcium signaling pathway
cAMP signaling pathway
Neuroactive ligand-receptor interaction
Vascular smooth muscle contraction
Parkinson's disease
Alcoholism
Pathway Interaction Database HIF-2-alpha transcription factor network
PathWhiz Pathway Intracellular Signalling Through Adenosine Receptor A2a and Adenosine
Reactome NGF-independant TRKA activation
Adenosine P1 receptors
G alpha (s) signalling events
Surfactant metabolism
WikiPathways Nucleotide GPCRs
Monoamine Transport
GPCRs, Class A Rhodopsin-like
NGF signalling via TRKA from the plasma membrane
GPCR ligand binding
GPCR downstream signaling
GPCRs, Other
References
Ref 523581ClinicalTrials.gov (NCT01410188) Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension. U.S. National Institutes of Health.
Ref 550203Clinical pipeline report, company report or official report of Acucela.